SEC Form SC 13G/A filed by Omeros Corporation (Amendment)
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/10/2025 | $9.00 | Buy | H.C. Wainwright |
| 12/23/2024 | $36.00 | Buy | D. Boral Capital |
| 11/14/2024 | $9.00 | Buy | Rodman & Renshaw |
| 12/8/2022 | $12.00 → $2.00 | Buy → Neutral | UBS |
| 11/8/2022 | $8.00 → $3.00 | Neutral → Underperform | BofA Securities |
| 6/8/2022 | $12.00 → $4.00 | Buy → Neutral | BofA Securities |
| 10/19/2021 | $19.00 → $12.00 | Buy | HC Wainwright & Co. |
| 10/8/2021 | Neutral → Underweight | JP Morgan |
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ:OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpatient settings. YARTEMLEA is the first and only approved therapy for
— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th
– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET – First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00
D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00
Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
SCHEDULE 13G - OMEROS CORP (0001285819) (Subject)
8-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch
— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th
– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET – First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wil
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G - OMEROS CORP (0001285819) (Subject)